A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma.

Forty-eight patients with advanced breast carcinoma who had not received prior chemotherapy (minimum follow up 21 months) were randomised to receive either adriamycin 70 mg m-2 i.v. 3-weekly for 8 cycles (Regimen A) or adriamycin 35 mg m-2 i.v. 3-weekly for 16 courses (Regimen B). Objective response...

Descripción completa

Detalles Bibliográficos
Autores principales: Carmo-Pereira, J., Costa, F. O., Henriques, E., Godinho, F., Cantinho-Lopes, M. G., Sales-Luis, A., Rubens, R. D.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1987
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001830/
https://www.ncbi.nlm.nih.gov/pubmed/3318902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001830/
https://www.ncbi.nlm.nih.gov/pubmed/3318902

Ejemplares similares